人才队伍

张英杰

时间:2021年08月28日 14:21 点击: 字体大小:

基本情况:

湖南大学,生命医学交叉研究院,副教授,博士生导师。河南郑州人,1983年生。2011年于华南师范大学获得生物物理博士学位,并于同年赴美国纽约大学医学院细胞生物学系进行博士后研究。2013年起在明尼苏达大学荷美尔医学研究所任荷美尔研究员,2015年受聘于湖南大学,现为副教授,博士生导师。主要研究方向为肿瘤遗传的分子机制及靶向治疗新方法的探索,近年来一直关注于细胞死亡、自噬和免疫的关系,及其在肿瘤治疗中的应用。主持国家自然科学基金1项,湖南省重大研发计划1项(子课题负责人),湖南省自然科学基金面上项目1项,深圳市科创委基础研究项目1项。在Theranostics, Cell Rep, J Controlled Release, Cell Death & Dis等多个著名国际期刊上发表论文20余篇,他引次数超过800。主讲课程《细胞工程》入选湖南省一流课程,荣获2019年湖南省高校教师课堂教学竞赛二等奖,2018年湖南大学讲课比赛一等奖。Tel18673177768;E-mailyingjiezhang@hnu.edu.cn


教育和培训经历:

2006-2011 华南师范大学生物光子学研究院,生物物理专业,博士

2011-2013 纽约大学医学院,细胞生物学系,博士后


工作经历:

2013-2015 明尼苏达大学,荷美尔医学研究所

2015-至今 湖南大学,生物学院&生命医学交叉研究院


学术兼职:

湖南省遗传学会会员

全国生物化学学会会员


研究领域:

1. 肿瘤遗传,免疫及转化医学;

2. 鉴定新的肿瘤治疗靶点并进行药物筛选;

3. 利用新型纳米/高分子材料进行肿瘤的靶向治疗;

4. 细胞死亡,自噬的分子机制和信号转导通路

5. 利用活细胞实时单分子成像和FRET研究蛋白的激活,时空转位及相互作用。


主持项目:

1. 湖南省重大研发计划子课题,2020DK2001,高稳定性转基因小鼠肿瘤模型构建的关键技术研发,2020/01-2022/1210万元,在研,主持

2. 湖南省自然科学基金面上项目,2020JJ4182突变体p53的获得性功能及其在淋巴瘤中的应用研究,2020/01-2022/125万元,在研,主持

3. 国家自然科学基金青年项目,31801140PUMA调控自噬的分子机制及其在结直肠癌中的功能研究,2019/01-2021/1226万元,在研,主持

4. 深圳市科创委基础研究项目,JCYJ20160530192802733PUMA在肿瘤自噬中的功能和分子机制研究,2017/03-2019/0230万元,已结题,主持

5. 中央高校基础科研项目,531107040909,靶向Akt治疗结直肠癌分子机制的研究,2015/09-2019/0820万元,已结题,主持


发表论文:

1. Jing Liu, Shuaiyu Long, Huanan Wang, Nannan Liu, Chuchu Zhang, Lingling Zhang and Yingjie Zhang*. “Blocking AMPK/ULK1‑dependent autophagy promoted apoptosis and suppressed colon cancer growth”. Cancer Cell International 2019; 19: 336. doi: 10.1186/s12935-019-1054-0. (IF: 5.722)

2. Yuan Huang, Nannan Liu, Jing Liu, Yeying Liu, Chuchu Zhang, Shuaiyu Long, Guang Luo, Lingling Zhang and Yingjie Zhang*. “Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA”. Cell Cycle 2019; 14: 1-14. (IF: 4.534)

3. Huanan Wang, Yeying Liu, Jie Ding, Yuan Huang, Jing Liu, Nannan Liu, Yue Ao, Yi Hong, Lefeng Wang, Lingling Zhang, Jiangang Wang and Yingjie Zhang*. “Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF-4E/PUMA pathway”. Cancer Gene Therapy 2019; doi: 10.1038/s41417-019-0117-7. (IF: 5.987)

4. Yeying Liu, Yuan Huang, Jie Ding, Nannan Liu, Shuang Peng, Jiangang Wang, Feng Wang and Yingjie Zhang*. “Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy”. Cancer Cell International 2019; 9(19): 124. (IF: 5.722)

5. Yingjie Zhang, Liming Nie, Keqian Xu, Yang Fu, Juchang Zhong, Kongzhen, Gu, Lingling Zhang. “SIRT6, A Novel Direct Transcriptional Target of FoxO3a, Mediates Colon Cancer Therapy”. Theranostics 2019; 9(8) 2380-2394. (IF: 11.556)

6. Jingfei Chen, Juchang Zhong, Yeying Liu, Yuan Huang, Fei Luo, Yingjun Zhou, Xi Pan, Shousong, Cao, Lingling Zhang, Yingjie Zhang*, Jiangang Wang*. “Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer”. Cancer Medicine 2018; 7(12): 6158-6169. (IF: 4.452)

7. Juchang Zhong#, Yingjie Zhang#, Jingfei Chen, Ruiying Huang, Yikun Yang, Haoxiang Chen, Yuan Huang, Weihong Tan, and Zhikai Tan. “In Vitro Study of Colon Cancer Cell Migration Using E-Jet 3D Printed Cell Culture Platforms”. Macromol Biosci 2018; 18(11): e1800205. (IF: 4.979)

8. Li Sun, Yuan Huang, Yeying Liu, Yujie Zhao, Xiaoxiao He, Lingling Zhang, Feng Wang and Yingjie Zhang*. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis”. Cell Death Dis 2018; 9(9): 911. (IF: 8.469)

9. Xianwang Wang, Xiaochun Peng, Xueqing Zhang, Hanyi Xu, Chengbiao Lu, Lian Liu, Jiaxing Song, Yingjie Zhang*. “The Emerging Roles of CIB1 in Cancer”. Cell Physi Biochemi 2017; 43: 1413-1424.

10. Zhikai Tan, Yikun Yang, Shurui Liao, Juchang Zhong, Yingjie Zhang*, Weihong Tan. “3D printed scaffolds for tumor targeting and controlled drug release”. J Controlled Release 2017; 259: e5-e195. (IF: 9.776)

11. Lingling Zhang, Huanan Wang, Wei Li, Juchang Zhong, Rongcheng Yu, Xinfeng Huang, Honghui Wang, Zhikai Tan, Jiangang Wang, Yingjie Zhang*. “Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis”. Oncotarget 2017; 8(2): 3289-3303.

12. Li Sun, Defeng Wang, Xiaotian Li, Lingling Zhang, Hui Zhang, Yingjie Zhang*. “Extracellular matrix protein ITGBL1 promotes ovarian cancer cell migration and adhesion through Wnt/PCP signaling and FAK/SRC pathway”. BIOMED PHARMACOTHER 2016; 81: 145-151. (IF: 6.529)

13. Lei Wang, Ji Wang, Hua Xiong, Fengxia Wu, Tian Lan, Yingjie Zhang, Xiaolan Guo, Huanan Wang, Mohammad Saleem, Cheng Jiang, Junxuan Lu, Yibin Deng. “Co-Targeting Hexokinase 2-Mediated Warburg Effect and ULK1-Dependent Autophagy Suppresses Tumor Growth of PTEN- and TP53-Deficiency-Driven Castration-Resistant Prostate Cancer”. EBioMedicine 2016; 7: 50-61. (IF: 8.143)

14. Huanan Wang, Lei Wang, Yingjie Zhang, Ji Wang, Yibin Deng, Degui Lin. “Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth” Cancer Cell Int. 2016; 16(16): 9. (IF: 5.722)

15. Huanan Wang, Lingling Zhang, Xu Yang, Yipeng Jin, Shimin Pei, Di Zhang, Yingjie Zhang* and Degui Lin*. “PUMA Mediates the Combinational Therapy of 5-FU and NVP-BEZ235 in Colon Cancer” Oncotarget 2015; 6(16): 14385-98.

16. Lei Wang, Hua Xiong, Fengxia Wu, Yingjie Zhang, Ji Wang, Liyan Zhao, Xiaolan Guo, Li-Ju Chang, Yong Zhang, M. James You, Shahriar Koochekpour, Mohammad Saleem, Haojie Huang, Junxuan Lu and Yibin Deng. “Hexokinase 2-Mediated Warburg Effect Is Required for PTEN and p53 Deficiency-Driven Prostate Cancer Growth”. Cell Rep 2014; 8: 1-14. (IF: 9.423)

17. Jie Feng, Yingjie Zhang and Da Xing. “Low-power laser irradiation (LPLI) promotes VEGF expression and vascular endothelial cell proliferation through the activation of ERK/Sp1 pathway”. Cellular Signalling. 2012; 24: 1116-1125. (IF: 4.315)

18. Yingjie Zhang and DaXing. “PUMA Promotes Bax Activation in a FOXO3a-dependent Manner in STS-induced Apoptosis”. J Innov Opt Health Sci 2010; 3: 31-38. (IF: 1.77)

19. Lingling Zhang, Yingjie Zhang and Da Xing. “LPLI Inhibits Apoptosis Upstream of Bax Translocation via a GSK-3β-Inactivation Mechanism”. J. Cell. Physiol. 2010; 224(1): 218-228 (Cover Story, Cited: 40). (IF: 6.384)

20. Yingjie Zhang, Da Xing and Lei Liu. “PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-XL during UV-induced apoptosis”. Mol. Biol. Cell. 2009; 20: 3077-3087. (IF: 4.138)

21. Yingjie Zhang, Da Xing and Lei Liu. “The molecular imaging study of PUMA and Bcl-2 family members in UV-induced apoptosis”. Chinese Journal of Lasers 2009; 36 (10): 2609-2613.

22. Yingjie Zhang* and Qun Chen. “PUMA Promotes Bax Translocation in FOXO3a-dependent Pathway during STS-induced Apoptosis”. Proc. of SPIE. 2009; 7519: 75191A1-9.

23. Lei Liu, Yingjie Zhang and Xianwang Wang. “Using FRET Technique to Investigate The Apoptotic Mechanism Induced by Cisplatin in Living Cells”. Progress in Biochemistry and Biophysics 2009; 36 (9): 1172-1179

24. Lei Liu, Yingjie Zhang and Xianwang Wang. “Involvement of Caspase-dependent and –independent apoptotic pathways in cisplatin-induced apoptosis”. Proc. of SPIE. 2009; 7178: 71780N1-8.

25. Yingjie Zhang, Da Xing, Yinyuan Wu and Lei Liu. “PUMA promotes Bax translocation by competitive binding to Bcl-Xl during UV-induced apoptosis”. Proc. of SPIE. 2008; 6857: 68570N1-10.


奖励与荣誉:

1. 主讲课程《细胞工程》入选2019年湖南省一流课程

2. 湖南省2019年普通高校教师课堂教学竞赛二等奖

3. 湖南大学2018年讲课比赛一等奖

4. 湖南大学2018年本科毕业设计(论文)优秀指导教师